United Therapeutics Corporation (FRA:UTH)

Market Cap	18.50B +20.1%
Revenue (ttm)	2.76B +2.5%
Net Income	1.15B +5.5%
EPS	24.46 +9.0%
Shares Out	n/a
PE Ratio	16.12
Forward PE	15.92
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	430.30
Previous Close	431.50
Day's Range	430.30 - 430.30
52-Week Range	342.00 - 522.80
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 28, 2026

About United Therapeutics

United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. It offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Nebulized Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of tre...

• Industry: Pharmaceutical Preparations
• Founded: 1996
• Employees: 1,400
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: UTH

Financial Performance

In 2025, United Therapeutics's revenue was $3.18 billion, an increase of 10.61% compared to the previous year's $2.88 billion. Earnings were $1.33 billion, an increase of 11.68%.

Financial numbers in USD

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Sep 19, 2026

Data Sources Report a data error